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The most effective intervention for the control of infectious disease is vaccination. The BCG 
vaccine, the only licensed vaccine for the prevention of tuberculosis (TB) disease, is only 
partially effective and a new vaccine is urgently needed. Biomarkers can aid the development 
of new TB vaccines through discovery of immune mechanisms, early assessment of vaccine 
immunogenicity or vaccine take and identification of those at greatest risk of disease 
progression for recruitment into smaller, targeted efficacy trials. The ultimate goal, however, 
remains a biomarker of TB vaccine efficacy that can be used as a surrogate for a TB disease 
end point and there remains an urgent need for further research in this area.
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It is clear that new tools are needed to achieve the ambitious goals of controlling tuberculosis (TB) 
set for 2025 and 2035 by the World Health Assembly, with the vision of a world free of TB [1,2]. It is 
estimated that, with optimized use of current tools, universal health coverage and improved social 
protection, we can achieve a rate of 25 TB cases per 100,000 a year by 2035 but, to ‘end TB’ by 2035, 
we will need new diagnostics, drug treatments and vaccines. It is also clear that biomarkers can play 
a role in the development of the new tools needed to end TB. This review will discuss what types 
of biomarkers and biosignatures are needed, and report on recent progress and new developments.
To start, it may be useful to define biomarkers. Biomarkers can be indicators of disease or of 
host immunity. In many or most cases, a combination of biomarkers will be needed rather than 
measurement of a single analyte, comprising a biosignature. In some cases, such biosignatures can 
act as surrogate markers for the protective efficacy of vaccines, as correlates of protection. In TB, 
these biomarkers can be developed to help control in different ways, some of which have made 
considerable progress in the last few years.
Biomarkers of vaccine efficacy
To control TB, a new and more protective vaccine than BCG is a priority. Although the first efficacy 
trial of the first new subunit candidate vaccine for the prevention of disease, MVA85A, has not 
shown significant protective efficacy when given to BCG-vaccinated infants in South Africa [3]; 
there is a pipeline of other new vaccine candidates [4]. If we could predict the likely efficacy of 
these vaccine candidates it would help to select the most promising candidates in preclinical or 
early clinical trials, reducing the risks associated with vaccine failure. To improve vaccine candidate 
selection we could improve animal models, use human challenge models and identify biomarkers 
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that correlate with TB vaccine efficacy. To date, 
correlates of protection have not been identified, 
although further results from studies in both 
BCG-vaccinated infants and adolescents and 
MVA85A-boosted infants are awaited. In a study 
by Kagina et al., measurement of polyfunctional 
T cells in BCG-stimulated whole blood cultures 
from BCG-vaccinated infants at 10 weeks of age 
did not discriminate between infants who subse-
quently progressed to TB disease and those who 
remained healthy, using intracellular cytokine 
staining and flow cytometry [5]. Polyfunctional 
T cells may not be protective, but it is also pos-
sible that in the Kagina study these cells were 
measured at the wrong time point, or the sample 
size may have been too small to see an effect. 
In a more recent study, BCG-specific IFN-γ 
measured by ELIspot was found to be associ-
ated with reduced risk of developing TB disease 
in the same South African infant population [6]. 
Although we have no confirmed or refuted cor-
relate due to the lack of efficacy with MVA85A, 
there is now low confidence in all TH1-boosting 
TB vaccine candidates and this has had a signifi-
cant impact on the TB vaccine pipeline (Figure 1). 
In 2013, there were 13 vaccine candidates in 
active clinical development for TB disease pre-
vention. Although there are currently ongoing 
TB vaccine clinical trials (ClinicalTrials.gov), 
many of these trials are research studies only, for 
example, investigation of new routes of vaccine 
delivery or for development of a human chal-
lenge model and the vaccine candidates used 
are no longer considered on a pathway toward 
efficacy testing. There has only been one new 
entry into the TB Vaccine pipeline since 2013 
(DAR 901) resulting in an overall contraction 
of the pipeline by 40% from 2013 to 2015. This 
is a concern as given that we have no confirmed 
biomarkers of vaccine efficacy; we need more 
data and should, therefore, be performing more 
clinical vaccine trials and not less.
Biomarkers of vaccine immunogenicity
Even though measuring cytokines has not to 
date provided a correlate of protection, these 
assays are very useful as biomarkers of vaccine 
immunogenicity. IFN-γ measured in diluted 
whole blood assays stimulated with purified 
protein derivative (PPD), provides a clear indi-
cation of BCG vaccination immunogenicity 
or ‘take’ in UK infants [8], while the IFN-γ 
ELISPOT was used in the early trials develop-
ing the MVA85A vaccine [9]. These assays can 
aid in dose finding and identifying the timing 
of any peak of immune responses following vac-
cination, thus contributing to decisions about 
the best time to administer a boosting vaccine. 
Thus we already have biomarkers that can help 
in the development of those new TB vaccine can-
didates in the development pipeline. However, 
these assays cannot, as so far performed, provide 
a correlate of protection, as they have neither 
been proved nor disproved as associating with 
vaccine induced protection.
Biomarkers for prevention of infection
The lack of TB vaccine efficacy trials is a direct 
consequence of the cost of performing such 
trials. Following exposure and infection with 
Mycobacterium tuberculosis there is a 10% life-
time risk of developing disease, although the 
greatest risk is within the first 2 years follow-
ing exposure [10]. In endemic populations, the 
annual incidence of disease is typically 1–2% 
requiring large numbers and lengthy follow-up 
to obtain sufficient sample size for an immune 
correlates analysis with a TB disease end point. 
One alternative is to use infection as an end 
point for immune correlates studies (prevention 
of infection [POI]) [11]. The annual incidence 
of TB infection is approximately five to tenfold 
higher than that of TB disease, substantially 
reducing the size and length of a vaccine efficacy 
trial [11]. Although attractive, there are caveats to 
this approach. We have limited tools available for 
the identification of TB infection (currently only 
the TST and IGRA) [12]. In addition, prevention 
of infection may not correlate with prevention of 
disease and there is a risk that candidates which 
could prevent disease (but not infection) will 
be missed. Vaccine candidates that show prom-
ise in a POI trial will have to be evaluated in 
a trial with a TB disease end point to confirm 
effectiveness against active disease [12].
Biomarkers for BCG replacement vaccines
Although we need a more effective vaccine 
for protection against TB, it is important to 
remember that BCG does provide protec-
tion against TB in some age groups and some 
populations [13]. In a recent meta-analysis of 
the literature, Mangtani et al. have shown that 
BCG protects in infancy and in those with low 
exposure to mycobacteria (measured by skin test 
reaction to PPD). The protective effect of BCG 
decreases with age of immunization and distance 
from the equator, likely because exposure to 
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Figure 1. The global pipeline of tuberculosis vaccine candidates 2013–2015. Vaccines for prevention of tuberculosis disease or 
prevention of infection in active clinical development 2013–2015. This does not include therapeutic vaccines. 
Data taken from [7].
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environmental mycobacteria or M. tuberculosis 
increases as age and proximity to the equator 
increase. In populations where BCG is protec-
tive the effect can last for up to 20 years or even 
longer [14]. Therefore, if we are to replace BCG 
with an alternative live attenuated vaccine we 
must ensure that the protective efficacy of the 
replacement vaccine is at least the same (non-
inferior) as that of BCG. The identification of 
a biomarker of BCG efficacy, which could then 
be measured in clinical trials of replacement 
vaccines, would greatly aid the development of 
a BCG replacement vaccine. In addition, there 
is evidence that BCG can provide nonspecific 
protection against all-cause mortality in infant 
populations in West Africa [15–19]. The exact 
mechanism of this protective effect is unknown 
although recent literature suggests that BCG 
may drive epigenetic changes in innate immune 
cells, improving innate capacity to control infec-
tion with other pathogens [20–22]. Thus, if we are 
to replace BCG we may have to show that the 
replacement vaccine is both noninferior in abil-
ity to protect against TB and in ability to protect 
against all-cause mortality. Conducting such tri-
als with clinical end points would be prohibi-
tively lengthy and costly and there is an urgent 
need to identify biomarkers of the nonspecific 
effects of BCG, which can then be measured 
in clinical trials of BCG replacement vaccines.
New approaches using mycobacterial 
growth inhibition
Another recent approach goes back to the core 
of the matter, the ability to kill or inhibit the 
growth of mycobacteria. These assays measure 
the summative ability of all innate, cell-mediated 
and humoral immune components in a sample 
to contribute to the control of mycobacterial 
growth. The exact immune mechanism does not 
need to be identified and the assay can be trans-
ferred between different animal species and into 
humans, providing a bridge between preclinical 
efficacy of vaccine candidates and potential for 
efficacy in early clinical trials. Assays measur-
ing mycobacterial growth have been used in a 
number of studies in recent decades, but have 
not proved easy to implement at scale or in vac-
cine trial settings [23–26]. However, mycobacte-
rial growth can now be quantitated automati-
cally using a mycobacterial growth inhibition 
assay, measuring the time to positivity using 
equipment available in many microbiology lab-
oratories [27]. Although further optimization of 
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this assay is needed, early indications are that 
BCG vaccination can induce the inhibition of 
mycobacterial growth [27]. Another approach is 
to perform this experiment in vivo in a human 
challenge study. This has been done by taking 
a biopsy of the BCG vaccination site and quan-
tifying the BCG present [28–30]. Future studies 
will seek to challenge human volunteers with 
attenuated strains of M. tuberculosis either by 
the intradermal or pulmonary routes although 
significant safety and regulatory concerns will 
have to be addressed before this can be done.
Biomarkers of infection versus disease
Biomarkers of infection or of risk of progres-
sion to disease could also contribute to both 
the development of diagnostic assays for TB 
and help to identify those at greater risk of pro-
gression, thus enabling smaller and less costly 
vaccine trials. Advances in flow cytometry have 
given us the ability to measure multiple mark-
ers expressed on both the surface and inside 
immune cells. Using combinations of cell sur-
face markers and intracellular cytokines or tran-
scription factors, we are able to characterize the 
cellular immune response in TB infection and 
disease to identify biomarkers of disease stage. 
TB disease stage can be identified through flow 
cytometry detection of monofunctional (single 
cytokine-expressing) or polyfunctional (multi-
ple cytokine-expressing) T cells. Polyfunctional 
T cells are increased in TB patients [31,32] and 
cells have been shown to be functionally and 
phenotypically different between TB patients 
and M. tuberculosis infected individuals [33–36]. 
However, whether flow cytometry can predict 
those at risk of developing future TB disease has 
not been tested.
Biomarkers of infection & treatment 
response: the power of gene expression 
signatures
There has been considerable progress using gene 
signatures as biomarkers for identifying infec-
tion or monitoring treatment response. These 
include signatures for active TB identified in a 
number of studies [37–41]. Such signatures can 
work in both HIV positive and negative sub-
jects, and in different geographical settings. 
Other ongoing studies aim to identify signa-
tures in cohorts of either adolescents or adults 
in highly TB-endemic settings [42]. Interestingly, 
such signatures can discriminate between active 
disease and infection and, thus, may improve 
on the existing diagnostic tests, such as skin 
testing, the QuantiFERON TB Gold In-tube 
test (Cellestis, Australia) or T-SPOT®.TB assay 
(Oxford Immunotec). A gene signature that 
would identify those progressing to clinical dis-
ease would enable early diagnosis and treatment, 
thus reducing transmission. Biosignatures that 
identify those at risk of developing disease before 
subclinical disease was present would, as noted 
above, help stratify participants in vaccine trials.
Gene signatures that normalize after success-
ful treatment of clinical TB may also give clues 
about biomarkers of infection [37–38,43]. Some 
individuals relapse following apparently suc-
cessful treatment, whereas most do not. Those 
with TB and diabetes mellitus are more difficult 
to cure and more likely to relapse than those 
with TB alone [44]. Such differences may provide 
additional indicators of what is needed to pre-
vent relapse. In summary, there may be a number 
of complementary approaches that could help us 
identify the components of a protective immune 
response. Meanwhile technology is developing 
too, and it is likely that by the time the com-
ponent parts of protective immunity have been 
identified, there will be simple and innovative 
ways in which to measure them in vaccine trials.
However, the ‘Holy Grail’ remains the identi-
fication of correlates of protection. It is sometimes 
said that we understand nothing about protec-
tion against TB, but this is not the case. Mice 
lacking the ability to make or respond to IFN-γ 
are more susceptible to disease as are humans 
with rare mutations in the IFN-γ/IL-12/STAT1 
signaling pathways [45–51]. We know that those 
with reduced CD4 T-cell numbers and func-
tion due to HIV infection become susceptible to 
TB. However, simple measures of CD4 T cells 
making IFN-γ, IL2 and TNF-α have not so far 
proved to provide a protective biosignature [3,52], 
although to date these have only been tested in 
one study as a correlate of TB risk [52].
The way forward
One issue here is that in the absence of clinical 
efficacy trials, how can such protective biosigna-
tures be identified? BCG does provide efficacy 
in some populations including infants and skin 
test negative school children [13]. Studies of BCG 
in these populations of sufficient size and length 
to include a TB disease end point could provide 
the case–control samples required for biomarker 
identification. Analysis of BCG specific immune 
correlates in samples from the failed MVA85A 
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infant efficacy trial provide an opportunity to 
identify biomarkers [3]. However, following the 
failure of the infant MVA85A trial, an on-going 
efficacy trial of MVA85A in HIV positive adults 
was downgraded to an extended safety study and 
there is now limited sample size for an immune 
correlates analysis in this study [53]. The only 
on-going efficacy trial with a TB disease end 
point is currently being performed with the vac-
cine candidate M72 in AS02 adjuvant. In this 
trial samples are being stored from all partici-
pants for retrospective biomarker analysis and 
it is critical that enough TB cases accrue during 
this trial to enable robust biomarker analysis in 
a case–control study. If this trial is terminated 
prematurely it could be decades before there is 
another opportunity to perform a correlates of 
risk study in a TB vaccine efficacy trial cohort.
Conclusion
Developing biomarkers of protective immunity 
is hard, when we do not have a full understand-
ing of the host response in TB. At the present 
time, we seem closer to identifying biosigna-
tures of infection and disease risk rather than 
of protection. Hopefully, there will be more to 
learn from ongoing studies, and particularly 
from both ongoing and future vaccine trials. 
We are obtaining a more objective view of the 
immunology of TB, guided by results from gene 
expression analysis using microarrays and now 
RNAseq. Measuring what really matters, the 
ability to kill or inhibit the growth of BCG or 
M. tuberculosis itself, may help, and also identify 
useful biomarkers. There are new approaches 
that should be explored, including the recent 
concepts of ‘memory’ or imprinting in innate 
immunity following BCG vaccination [20], more 
in depth analyses of memory T cells including 
epigenetic approaches, exploration of humoral 
immunity and insights from systems biology. 
To bring these different approaches together, 
some coordination of effort will also be useful, 
as can be achieved through biomarker work 
packages in large research consortia, such as the 
TBVAC2020 consortium recently funded by the 
EU [54], or the plans for a Global TB Vaccine 
Partnership to provide coordination between 
ongoing work funded by the Bill & Melinda 
Gates Foundation and that funded by the EU.
Future perspective
In the next 5–10 years, there will be reinvig-
oration of the TB vaccine clinical trials pipeline 
with the entry of candidate TB vaccines funded 
through Horizon 2020, the Bill & Melinda Gates 
Foundation, EDCTP and other funders. There 
is a drive to develop TB vaccine candidates that 
are not focused on boosting a Th1-type immune 
response, although the Th1 concept has been nei-
ther confirmed or refuted as important in vaccine 
induced protection. There is an urgent need for 
biomarkers that can select the most promising of 
these TB vaccine candidates for accelerated clinical 
development. A rapid and immediate acceleration 
in biomarker research is required in preparation for 
the screening of large numbers of new entry TB 
vaccine candidates in the next 5–10 years.
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EXECUTivE SUMMARY
 ●  Biomarkers can aid the development of new tuberculosis (TB) vaccines in multiple ways.
 ●  Biomarker research has identified immune mechanisms of TB disease that have potential importance for the design of 
new TB vaccine candidates.
 ●  Monitoring of TB vaccine immunogenicity can be performed effectively with biomarkers.
 ●  Biomarkers can be used to shorten the length of TB vaccine efficacy trials by focusing recruitment on individuals at 
greatest risk of developing TB disease.
 ●  The ‘Holy Grail’ remains a biomarker of TB vaccine efficacy that can be used as a surrogate for a TB disease end point.
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